This pharma player's $90 million breakthrough could soon double the market's return

Please do not reply to this message, as replies are routed to an unmonitored mailbox. You are receiving this email as a part of your subscription to Strategic Tech Investor. Your ability to alter your subscription information can be found at the bottom of this email. [Strategic Tech Investor] [You need to drop everything and see this (there could be millions at stake)]( Canada just went fully legal - and the countdown to legal sales has officially begun. The end of their nearly century-long era of prohibition has arrived, and it's [unlocking a profit opportunity]( like nothing we've ever witnessed. This news has already sent pot stocks soaring, but with billions of dollars in revenue expected to start flowing in just weeks, we're just getting warmed up. We've tracked down the next generation of piping-hot companies that could hand you a chance at life-changing profits - but only if you know [how to get in on the ground floor](... --------------------------------------------------------------- June 26, 2018 [This Pharma Player's $90 million Breakthrough Could Soon Double the Market's Return]( By Michael A. Robinson Dear Strategic Tech Investor Reader, LATEST REPORT --------------------------------------------------------------- LATEST APPEARANCE --------------------------------------------------------------- [Exclusive Video - Live From Silicon Valley's Biggest Blockchain Event]( MICHAEL'S LATEST ALERTS --------------------------------------------------------------- Research [This Visionary Tech CEO Is Delivering Us Huge Gains]( Trading [Taking Advantage of the Fear Trade with Our Advanced Kidney Care Play]( We're coming up on the one-year anniversary of an event set to have a big impact on the future of drug discovery. And yet, it flew right under Wall Street's radar screen. Maybe that's because a $90 million investment seems like small potatoes for the global drug industry - one that Evaluate Pharma says will be worth $1.1 trillion by 2022. Here's the thing though. Big Pharma player Eli Lilly &Co. (NYSE: [LLY](), said last June 21 that it had reopened its Biotechnology Center in San Diego after a big upgrade. That event got scant attention beyond in the local press. But it should have. The reason? This new facility may very well mark the drug industry's research tipping point. That's because this state-of-the art facility is virtually brimming with advanced automation and robotic systems. Lily's center has already shown a five-fold increase in its ability to screen antibodies for new drugs. And today, I'm going to tell you how to play this breakthrough with an investment that is doubling the market's return... --------------------------------------------------------------- [Your Time Is Running Out]( In as little as five days from now, you could receive a lump-sum check for up to $23,441 from the Social Security Administration. You must move quickly, though - depending on your situation, there's a specific time period that the SSA will give you to claim unpaid money. [Learn more here](. --------------------------------------------------------------- This Twofer Play Will Get You There It's easy to see why Big Pharma is anxious to invest in faster drug research. Currently, it can easily cost more than $1 billion and take more than a decade to bring a new drug to market. Of course, clinical trials themselves run well into the seven figures, and can take as long as five years before a new drug receives federal approval. That's a process that might take a while to improve. However, the front-end of drug research is ripe for disruption. Let me explain... The online research journal CompoundChem.com says early stage lab work needed to find potential products can take up to six years to carry out. Not only that, but researchers need to screen up to 10,000 possible targets just to find one that works. But by the end of this year, Lilly hopes to have collapsed five years' worth of R&D into one. That's because they will have screened some 50,000 antibodies that can form new drugs spanning up to 40 new projects. Viewed against this backdrop, Lilly's new $90 million investment in its state-of-the-art facility could produce rich rewards. To hit these milestones, Lilly teamed up with BioServe, a privately held startup that focuses on robotics and automation software. That means there is no direct way for us to invest in this key supplier firm. And while I respect Lilly as a great drug firm, buying shares directly at this point doesn't really give us much access to the robotics and automation software that's changing industries far beyond drugs and biotech. --------------------------------------------------------------- [Did the FCC just hand you your next huge payday opportunity?]( With a stroke of its pen, the FCC has granted approval for a breakthrough device that's about to c[hange all of our lives](... forever. You see, we're on the brink of a complete global energy overhaul, and right now, [one tiny company]( has the key to it all. If you want to be poised for the biggest, most life-changing gains, you better [strike now](. --------------------------------------------------------------- That's why I continue to recommend the Robo-Stox Global Robotics & Automation ETF (Nasdaq: [ROBO](). This is actually a twofer play. First, it's a great way to invest in the long term trend in the types of AI-powered robotics and automation that are finding their way into factories and R&D labs around the world. International Data Corporation says worldwide spending on robotics and related services will hit $135.4 billion in 2019. That's more than double the $71 billion spent in the base year of 2015. Second, the fund also is investing in robotic-oriented medical firms. Plus, as a bonus, we gain access to the 3D printing and advanced semiconductors firms that are driving these fields forward at a rapid pace. Take a look: - Mazor Robotics Ltd. (Nasdaq: [MZOR]() is a fast-growing maker of a robotic guidance systems for spine surgery. A survey of doctors who have used it shows the equipment performs surgeries with 98.3% accuracy. That, in turn, translated into a 56% reduction in unnecessary follow-up X-ray scans, a 48% drop in post-surgical complications and a 46% drop in the need for a second spinal surgery. The company also stands to profit from an exclusive arrangement to supply the Mazor X system to Medtronic Plc (NYSE: [MDT](). - Novanta, Inc. (Nasdaq: [NOVT]() supplies motion and other platforms used in medical robots, part of a market it says is worth $20 billion. The firm also sells photonics, vision and precision motion gear that is helping a range of clients in advanced manufacturing and healthcare. Its' life sciences unit makes equipment for use in areas like DNA sequencing. And about half of last year's $523 million in sales came from its medical unit. - Accuray Inc. (Nasdaq: [ARAY]() is a small-cap firm know as a leader in cancer therapy. But much of this relies on the use of automated systems. It makes the RoboCouch for precise patient positioning. Plus, it supplies the CyberKnife robotic radiosurgery device for non-surgical treatment of tumors and lesions located just about anywhere in the body. The device even provides real-time tumor tracking and motion management. - Cognex Cp (Nasdaq: [CGNX]() is a world leader in machine vision. It also supplies software, vision sensors and industrial ID readers used in manufacturing automation. These systems are used to guide assembly robots, but also to track, sort, and identify products. Cognex is as a key supplier to Apple Inc. (Nasdaq: [AAPL]() for its vision systems that can detect product defects - a key part of quality control. - Nvidia Corp. (Nasdaq: [NVDA]() makes a series of advanced graphics processing units (GPUs) that lie at the heart of a $2.86 trillion sector about to sweep over the market... I'm talking about virtual reality (VR). These are also used in deep learning and AI. More to the point, Nvidia's GPUs are also used in drones, industrial robotic systems, for self-driving car features and even in cryptocurrency mining. In its most recent quarter, Nvidia saw sales jump 32% to a record $2.6 billion. Do Like Biotech's CEOs Do Now then, ROBO's 0.95% expense ratio is higher than I generally like to see in a stock. But I am making an exception here because this appears especially well-built to capture the field's sizzling growth. And it is greatly beating the overall market. Over the past two years, ROBO is up roughly 70.4%. That's just at double the S&P 500's profits of 34.4% over the same period. Launched in late November 2013, this relatively young fund still faces plenty of upside. Moreover, as it's priced at just $42.50 a share, ROBO trades at a fraction of some of its notable portfolio holdings. In other words, with this one play we get the safety of owning a group of stocks, along with their high performance results. Think of it this way. You're building your net worth in a method similar to the biotech leaders who are now discovering the next generation in drugs - by automating it. Now, I've showed you that firms taking advantage of the breakthroughs happening in the hot AI and robotics field are set to soar. But there's another, tiny Silicon Valley company that's sending shockwaves throughout the tech world that's poised to [accelerate your net worth even further](. And the FCC just approved [this device]( that's capable of doing something most people thought was impossible. The Washington Times says the [technology behind the device](, "will change the world on a scale hardly seen in human history." [You need to see this to believe it](... Here's what else I'm following... --------------------------------------------------------------- [Breaking: China's Deadly Battle Plan Set into Motion]( [Shocking satellite images]( prove the Chinese are now more hostile than ever. A fatal battle plan is unfolding in the South China Sea that could be deadlier than Pearl Harbor and 9/11 COMBINED. At the center is a deadly superweapon so powerful, it's like the equivalent of firing a missile from New York City and hitting a target in Miami in less than 12 minutes. Their battle plan is already set into motion... so this isn't a "what if" scenario - it's a "right now" emergency. You owe it to yourself and your family to [see this immediately]( - before it's too late. [Consumer Reports May Like Tesla - but We Like This Stock Even More]( Last month, Consumer Reports revealed that the Model 3 from Tesla Inc. required a highly dangerous 152 feet to stop from 60 mph. That's bad. However, Tesla was able to fix the problem with a wireless "over the air" software update. In other words, thousands of auto owners got their cars fixed without having to trek to their dealership or a mechanic. That's good. It's a technological feat that would have been impossible as recently as five years ago - and it gives us a great look into the future of the entire industry. As stunning as this achievement is, I can't recommend the stock. Fact is, Tesla remains a very choppy, money-losing trade. However, there is a tech-centric auto industry out there that I am recommending. [Check it out here](... What an Ancient Madman Can Teach Us about the Market It's fun to draw lessons from history, especially when that history provides something that we can apply to finance. Consider the story about Antiochus Epiphanes, the leader of the Seleucid Empire, often called "the madman" because of his eccentric behavior. Antiochus was told by the Roman envoy, Gaius Popilius Laenas, to withdraw his army from their approach of Rome or be considered at war with the empire. This was the famous "drawing a line in the sand" from which the expression was derived. Sign up for D.R. Barton's free twice weekly Sure Money Investor, and he'll explain how this expression applies to the key support levels that we have seen tested in the market lately, and why we can expect the market to continue its upward climb. [Click here to sign up](. [It's Time to Change the Way You Think About AI]( Citigroup is looking to cut half of its 20,000 tech and operations staff and replace them with artificial intelligence other forms of automation. Goldman Sachs is looking to do something similar. People are scared - and I get it. But there's a much bigger story here - and it's a positive one for job seekers. It's a positive story for technology investors, too. So, let's discover how AI-driven automation is actually sparking a jobs boom. [And let's dig up a hidden way to play this field with a stock that I think will double in less than 30 months](... YOU MAY HAVE MISSED... --------------------------------------------------------------- [This Is Your Last Chance to Turn a Tiny Stake Into Marijuana Millions]( [Take Back America's Most Important Safety Net]( [Every Nation on Earth Is About to Be Transformed by This Stunning New Technology]( [The Chinese Are About to Learn This Very Valuable Lesson]( --------------------------------------------------------------- [Facebook]( [Twitter]( [More...]( mailto:?subject=Michael%20Robinson's%20Strategic%20Tech%20Investor&body=Check%20out%20http%3A%2F%2Fwww.strategictechinvestor.com%2F You are receiving this e-mail at, {EMAIL}, as a part of your free subscription to Strategic Tech Investor. Remove your email from this list: [Unsubscribe]( To cancel by mail or for any other subscription issues, write us at: Strategic Tech Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 [Contact Customer Service]( Website: [( © 2018 Strategic Tech Investor All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Strategic Tech Investor. 1125 N Charles Street, Baltimore MD 21201.